TY - JOUR T1 - A new model to prioritize waiting lists for elective surgery under the COVID-19 pandemic pressure JF - medRxiv DO - 10.1101/2020.07.21.20157719 SP - 2020.07.21.20157719 AU - Roberto Valente AU - Stefano Di Domenico AU - Matteo Mascherini AU - Gregorio Santori AU - Francesco Papadia AU - Giovanni Orengo AU - Angelo Gratarola AU - Ferdinando Cafiero AU - Franco De Cian AU - Enzo Andorno AU - Giulia Buzzatti AU - Susan Campbell AU - Walter Locatelli AU - Marco Filauro AU - Marta Filauro AU - Marco Frascio AU - Carlo Introini AU - Franca Martelli AU - Guido Moscato AU - Giorgio Orsero AU - Giorgio Peretti AU - Paolo Pronzato AU - Edoardo Raposio AU - Mirella Rossi AU - Stefano Scabini AU - Nicola Solari AU - Carlo Terrone AU - Luca Timossi AU - Giovanni Ucci Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/05/2020.07.21.20157719.abstract N2 - The COVID-19 pandemic burdens non-covid elective surgical patients by reducing service capacity, forcing extreme selection of patients most in need. Our study assesses the SWALIS- 2020 model ability to prioritize access to surgery during the highest viral outbreak peaks.A 2020 March - May feasibility-pilot study tested a software-aided, inter-hospital, multidisciplinary pathway. All specialties patients in the Genoa Surgical Departments referred for urgent elective patients were prioritized by a modified Surgical Waiting List InfoSystem (SWALIS) cumulative prioritization method (PAT-2020) based on waiting time and clinical urgency, in three subcategories: A1-15 days (certain rapid disease progression), A2-21 days (probable progression), and A3-30 days (potential progression). We have studied the model’s applicability and its ability to prioritize patients by monitoring waiting list and service performance. https://www.isrctn.com/ISRCTN11384058.Following the feasibility study (N=55 patients), 240 referrals were evaluated in 4 weeks without major criticalities (M/F=73/167, Age=68.7 +/- 14.0). Waiting lists were prioritized and monitored. The SWALIS-2020 score (% of waited-against-maximum time) at operation was 88.7 +/- 45.2 at week 1 and then persistently over 100% (efficiency), over a controlled variation (equity), with a difference between A3 (153.29 +/- 103.52) vs. A1 (97.24 +/- 107.93) (p <0.001), and A3 vs. A2 (88.05 +/- 77.51) (p <0.001). 222 patients underwent surgery, without related complications or delayed/failed discharges.The pathway has selected the very few patients with the greatest need, even with +30% capacity weekly modifications, managing active and backlog waiting lists. We are looking for collaboration for multi-center research.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN11384058Funding StatementThe study has not received any external or ad hoc funding. Alisa contributed to maintaining the coherence of the study with institutional directives, and finally reviewing the manuscript. The corresponding author (RV) confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Liguria Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are/will be available upon request from Mr Roberto Valente (Roberto.valente{at}hsanmartino.it) and Dr Stefano Di Domenico (Stefano.didomenico{at}hsanmartino.it). The dataset is in an MS Access TM format, and can be anonymized to any level required, as allowed by the Liguria Ethics Committee. The dataset will be made available 3 months after study completion, for 12 months, extendable. Any sharing request will be submitted to the Liguria Ethics Committee for approval. ER -